Clinical · Molecular biology
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study
Summary
The Phase II ORCHARD study investigated resistance mechanisms to first-line osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Utilizing next-generation sequencing (NGS) on both tissue and plasma samples, the study characterized the molecular profile of tumors after progression. Resistance alterations were detected in 87% of samples, often multiple, involving genes such as TP53, MDM2/4, PI3K, SOX2, and MYC. These findings highlight the heterogeneity of resistance and provide a rationale for exploring combination therapies to improve patient outcomes.
Critical appraisal
Clinical. The ORCHARD study is a Phase II biomarker-directed trial designed to inform second-line treatments following progression on first-line osimertinib. The exploratory findings reveal heterogeneous resistance patterns, suggesting that broad-activity combination therapies might be more effective. This provides a strong rationale for designing future clinical trials to evaluate novel therapeutic strategies based on these complex resistance profiles. Clinical impact could be seen within 3-5 years with the initiation of new trials, and potentially beyond 5 years for changes in clinical practice.
Molecular biology. This analysis employed next-generation sequencing (NGS) on both tumor biopsies (n=400) and plasma samples (n=191) to provide a comprehensive genomic profile. It identified frequent alterations in TP53 and MDM2/4, as well as in the PI3K pathway, SOX2, and MYC, particularly in histologically transformed tumors. The detection of multiple resistance alterations in nearly half of the samples (46%) and an overall detection rate of 87% underscore the complexity of resistance mechanisms. These discoveries provide a solid foundation for the development of predictive biomarkers and novel targeted or combination therapies, potentially validated through future clinical tests.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology